Scientists Evaluate the Benefit of Novel Beta Cell Survival

For nearly 100 years, it is known that type 1 diabetes (T1D) is a disease fundamentally about the progressive loss of insulin-producing beta cells. But measuring that loss has continued to elude researchers — at least until now. In a recent scientific publication, JDRF-funded researchers used a radiotracer or marker and PET (Positron Emission Tomography) scanning as a non-invasive technique to follow changes in how many active beta cells a person has.

Dr. Olle Korsgren and his colleagues at the University of Uppsala in Sweden used the technique in a clinical study of 10 people with T1D and nine without the disease to compare the amount of beta cells in each group. They found the amount or volume of active beta cells was significantly lower in the group with T1D compared to those without T1D, and the reduction was close to what researchers predicted given a loss of the majority of beta cells in the pancreas in T1D. In another study of people with type 2 diabetes, the researchers were able to use the technique to detect a progressive loss of the amount of beta cells in one person imaged repeatedly over a two-year period.

The PET imaging technique is based on recently discovered biological processes that take place in the beta cell. One specific process in the beta cell causes the cells to take up a commonly used imaging radiotracer administered at the beginning of the procedure. The amount of the tracer that is deposited in the pancreas primarily depends on how many beta cells are alive and active. The PET scan can then detect the amount of radiotracer in the pancreas as an approximate measure of the overall amount or volume of beta cells present. The procedure takes only a few hours to complete.

This imaging technique will most likely have no role in diagnosing T1D because of the large variability of the number of beta cells among people with T1D and even among those without T1D. However, it could become a key tool for tracking the loss of beta cells in a person at risk of T1D and as a faster and more precise way to evaluate the benefit of novel beta cell survival and regeneration therapies. More human validation studies of this technique are needed before it can be used routinely.

Source-Eurekalert